Switch to:
Alexion Pharmaceuticals Inc (NAS:ALXN)
Research and Development
$712 Mil (TTM As of Jun. 2016)

This is the expense the company spent on research and development. Alexion Pharmaceuticals Inc's research and development for the three months ended in Jun. 2016 was $179 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2016 was $712 Mil.


Definition

This is the expense the company spent on research and development.

Alexion Pharmaceuticals Inc Research & Development for the trailing twelve months (TTM) ended in Jun. 2016 was 165.664 (Sep. 2015 ) + 191.035 (Dec. 2015 ) + 176.29 (Mar. 2016 ) + 179.311 (Jun. 2016 ) = $712 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Alexion Pharmaceuticals Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 8369638298137223317514709

Alexion Pharmaceuticals Inc Quarterly Data

Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16
Research & Development 93101129221132166191176179196
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK